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Abstract
Introduction: Gonadotropin-releasing hormone analogs (GnRHa) are the treatment of choice for CPP. We
investigated growth in GnRHa-naïve subjects, treated with leuprolide acetate 1-month depot for CPP.
Methods: This prospective, open-label study had a long-term, observational, follow-up period. Forty-nine females
and 6 males were enrolled. Leuprolide acetate depot was administered intramuscularly every 28 days. Height and
growth rate during and after treatment until adulthood were measured.
Results: Among 30 of 49 females having an adult height (AH) measurement, 29 had target heights available
(mean = 163.8 cm) and 27 had pretreatment predicted adult heights (PAHs; mean = 157.4 cm). After treatment,
the mean AH at mean age 21.8 years [range 13.7-26.7 years] was 162.5 cm, a mean height gain over baseline PAH
of 4.0 cm. The mean height standard deviation score was -0.1 at AH.
Conclusions: Treatment of CPP with leuprolide acetate 1-month depot had beneficial effects on growth rate and
preservation of AH.
Trial Registration: ClinicalTrials.gov: NCT00660010
Introduction
Central precocious puberty (CPP) commonly refers to
the development of pubertal sex characteristics as a con-
sequence of the premature activation of the hypothala-
mic-pituitary-gonadal (HPG) axis before the age of 8
years in girls and 9 years in boys. The pathogenesis of
CPP includes early activation of pulsatile release of
gonadotropin-releasing hormone (GnRH), leading to an
increase in secretion of gonadotropins and gonadal ster-
oids. Central precocious puberty occurs much more fre-
quently among females than males (greater than 20:1
ratio) [1].
The treatment goals for children with CPP include
hormonal suppression, regression or cessation of
development of pubertal characteristics and the preven-
tion of short stature in adulthood. Patients with CPP are
at risk of short stature in adulthood because of dispro-
portionately advanced skeletal maturation in relation to
growth acceleration, resulting in early epiphyseal fusion
that limits growth potential [2].
Analogs of GnRH (GnRHa) have been the standard of
care for the treatment of children with CPP for more
than 20 years [2], with the usage of the depot form
reported in 1989 [3]. However, despite the widespread
use of GnRHa in the treatment of CPP, the factors that
impact adult height outcomes after GnRHa therapy in
children with CPP are poorly understood [4-13].
The few previous studies that have examined out-
comes during and after treatment with leuprolide acet-
ate have utilized variable treatment doses, and generally
small numbers of patients [14-16]. The objectives of this
longitudinal, prospective study were to evaluate the
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any medium, provided the original work is properly cited.suppression of hormonal and clinical sexual characteris-
tics and to examine the long-term impact of baseline
and during-treatment factors on the growth pattern and
adult height after treatment with leuprolide acetate 1-
month depot in females with CPP. In this report, we
describe the auxological outcomes of the study and ana-
lyze the effect of multiple baseline and during-treatment
factors that potentially affect height outcomes in
females. Though males were included in the study, firm
conclusions regarding height outcomes cannot be drawn
due to the small sample size. However, brief descriptive
results have been included herein. A separate article
reports the hormonal and reproductive outcomes of the
study [17].
Patients and Methods
Patients
Patients were females with Tanner breast stage ≥2
before 8 years of age whose chronological age (CA) was
less than 9 years. Males with Tanner genitalia stage ≥2
before 9 years of age whose CA was less than 10 years
were also included. All had a baseline GnRH-stimulated
LH level ≥10 IU/L. This level was chosen to ensure that
all enrolled patients clearly had CPP, even though it was
realized that some patients with CPP would be excluded.
Additional inclusion criteria were bone age (BA)
advancement ≥1y e a ro v e rC Ab yt h eF e l sM e t h o d[ 1 8 ] ,
and treatment naïve to GnRHa. Institutional review
board approval was obtained at each site, and written
informed consent was provided by patients’ parents or
legal guardians prior to screening or any study related
procedures.
Study Design
This was a prospective, longitudinal, multicenter study
that consisted of an open-label treatment period and a
long-term post-treatment follow-up period. The study
was conducted from 1991 to 2009 at nine U.S. centers.
The primary outcomes of treatment in the study were
the assessment of clinical sexual characteristics evalu-
ated by Tanner staging and the decrease in serum gona-
dotropin and sex steroid concentrations to prepubertal
levels. During the long-term follow-up into adulthood,
the outcomes were adult height (based on stadiometer
measurement or self-reported by questionnaire as
adults) and information reported concerning reproduc-
tive system function.
Leuprolide acetate 1-month depot was started at a dose
of 300 μg/kg (minimum starting dose of 7.5 mg) adminis-
tered intramuscularly (IM) every 28 days. Incremental
dose adjustments of 3.75 mg were made at each clinic
visit, if necessary, based on the results of the previous
GnRH stimulation test and hormonal parameters. GnRH
stimulation tests for LH were performed by using a
standard method (Factrel 100 μg IV bolus) in all patients.
LH concentrations were measured by using DELFIA™
with a lower limit of quantitation of 0.15 IU/L.
Treatment period visits occurred at weeks 4, 8, 12,
24, 36, 48, and then every 6 months until study drug
discontinuation. Study procedures included a physical
examination with measurement of height and weight,
assessment of Tanner stage, GnRH stimulation testing,
and blood collection for gonadotropin and sex steroid
levels. Bone radiographs were taken at baseline, week
24, week 48, and every 12 months thereafter. Radio-
graphs were sent to a central reader (Wright State
University School of Medicine, Lifespan Health
Research Center, Kettering, OH) for determination of
BA using the Fels Method [18]. Levels of gonadotro-
pins and estradiol were determined by dissociation-
enhanced lanthanide fluorescence immunoassay and
radioimmunoassay, respectively (University of Pitts-
burgh Children’sH o s p i t a l ;P i t t s b u r g h ,P A ) .T a r g e t
height was calculated by mid parental height plus or
minus 6.5 cm for males and females, respectively; tar-
g e th e i g h tr a n g ew a sc a l c u l a t e db yt a r g e th e i g h t±8 . 5
cm. Predicted adult heights (PAH) were calculated by
dividing a subject’s height by the average percent of
mature height associated with a given BA. The average
percents of mature height were derived from tables for
accelerated boys and girls prepared by Bayley and Pin-
neau [19]. Study drug was discontinued at the appro-
priate age for puberty at the discretion of the
investigator.
After study drug withdrawal, patients entered into an
optional follow-up period, with study visits occurring
every 6 months until physical and laboratory measure-
ments reached pubertal levels, and then annually until
age 21 years. Follow-up study visits included a physical
examination with measurement of height and weight,
Tanner staging, basal levels of gonadotropins and sex
steroids after evidence of pubertal response was
observed with stimulated levels, menstrual and sexual
history, and bone radiographs of the left hand and wrist.
Adult height data were collected at adulthood (after age
18), during an office visit or by a patient-reported ques-
tionnaire (n = 19). For patients who were missing adult-
hood height data, adult height was established if the
final height obtained during follow-up was associated
with a growth velocity of <1 cm/year or a BA ≥14 years
in females (n = 11) or ≥15 years in males.
Statistics
Mean incremental growth rate was calculated as the
ratio of the change in height to the change in CA at
approximately six month intervals (1 month = 28 days
to match dosing interval) during the treatment period
and through the first year of the follow-up period, and
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growth rate was calculated as the growth rate during the
year prior to the start of the treatment period.
The ratio of the change in BA during each one year
interval to the change in CA during the one year inter-
val was computed. Mean height and mean height stan-
dard deviation score (HtSDS) were calculated at each
visit during the treatment and the follow-up periods and
at adult height.
Pearson’s correlation coefficients were calculated
between baseline characteristics (CA, BA, BA-CA, time
to treatment from onset of CPP, basal and peak LH,
basal and peak FSH, growth rate, height SDS and target
height), during-treatment variables (duration of treat-
ment, average growth rate, the mean ratio of change in
BA to change in CA, mean basal and peak LH, and
mean basal and peak FSH), and end of treatment vari-
ables (CA, BA, BA-CA, growth rate, and height SDS)
and gain over baseline PAH, height gain over end of
treatment height, and at adult height. Dependent vari-
ables that were statistically significantly correlated at a
= 0.05 level with each auxological outcome were entered
into a stepwise multiple regression analysis to determine
the best predictors (statistically significant at a =0 . 0 5
level) of each auxological outcome.
Results
Female Patients
This study consisted of a mean ± SD treatment period
of 3.9 ± 2.0 years and a post-treatment follow-up per-
iod of 3.5 ± 2.2 years [17]. The study enrolled both
females and males, however, too few males (n = 5)
were enrolled to draw conclusions, and, therefore,
were not included in the primary analysis presented in
this report. Forty-nine females were enrolled in the
treatment period and 35 of them participated in the
long-term follow-up period (Figure 1). No premature
discontinuations (n = 9) were related to lack of effi-
cacy. All patients were naïve to treatment with
GnRHa. Patient demographics and baseline character-
istics for the female study population are summarized
in Table 1. Overall, 61.2% of patients were Caucasian.
At baseline, the mean age was 7.3 years and BA was
advanced over CA by an average 3.0 years. Overall, the
mean time since diagnosis of CPP was 0.3 years in the
study population. All subjects had peak stimulated LH
suppressed to <1.75 IU/L during treatment with leu-
prolide acetate 1-month depot, with 5 subjects requir-
ing an increased dosage to obtain or retain suppression
over the course of treatment. After discontinuation
from study drug, the mean ± SD time to first menses
was 1.5 ± 0.5 years (range of 0.5-2.5 years). The gona-
dotropin and sex steroid data are discussed in detail in
a separate paper.
Growth During Treatment
The mean incremental growth rate was greatly reduced
from 10.6 cm/year at baseline to approximately 5-6
cm/year during the first 72 weeks of therapy and then
4-4.5 cm/year from week 72 to week 192 (Figure 2).
These mean growth rates during treatment were gen-
erally comparable to normal growth rates in prepuber-
tal girls.
Post-treatment Growth
During the last 6 months of treatment, among patients
who were enrolled into the follow-up period of the
study, the mean incremental growth rate was 4.0 cm/
year. Following withdrawal of study drug, mean incre-
mental growth rate increased to 4.4 cm/year (Figure 2)
at the 24 week follow-up visit, showing a small growth
spurt, before gradually decreasing to 0.4 cm/year by fol-
low-up week 192.
Bone Age and Predicted Height
Prior to the initiation of treatment, mean BA advance
over CA was 3 years. Treatment with leuprolide acetate
1-month depot rapidly controlled the advance in BA,
with mean ΔBA/ΔCA of 0.7 after the first year of treat-
ment, and not more than 0.6 in during the next 3 years
of treatment (Figure 3).
Adult Height and Height Gain
Among the 30 females with adult height data, 29
females had a mean target height of 163.8 cm at base-
line, and 27 subjects had a mean PAH of 157.4 cm at
baseline. Of the 30 females with adult height data, 22
were measured with stadiometer, and 8 were self-
reported. The mean adult height was 162.5 cm, which
represents a mean height gain over baseline PAH of
49 patients enrolled and 
dosed (ITT population)
40 patients
completed the study
35 patients entered the follow-up 
period and had measurement of 
adult height 
9 discontinued
4 request to leave study
5 noncompliant with study visit schedule
3 lost to follow-up
1 adverse event
Figure 1 Patient disposition. Flow of female patients through the
trial. Patients may have had more than one reason for treatment
discontinuation.
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Page 3 of 94.0 cm. (Figure 4). In addition, mean height SDS was
-0.1 at adult height, indicating that these patients
essentially reached the mean height of the normal
population by adulthood (Figure 5). Among the 29
females with menarche status at baseline and adult
height, subjects who were premenarchal (n = 22) or
post-menarchal (n = 7) had similar mean ± SD adult
height outcomes (162.8 ± 6.77 cm vs 162.0 ± 1.6 cm,
respectively).
Analysis of Factors Potentially Predictive of Height
Outcomes
Univariate analyses were performed to identify factors
that were strongly correlated with adult height, height
gain over baseline PAH, and height gain after treatment
(Tables 2, 3, and 4). After stepwise multiple linear
regression of the factors that were significantly corre-
lated in the univariate analysis, there were significant
positive associations of average growth rate during treat-
m e n t( p=0 . 0 0 0 2 )a n dh e i g h tS D Sa tb a s e l i n e( p<
0.0001) with adult height (Table 2). For height gain over
baseline PAH, BA minus CA at baseline (p = 0.0028)
and time to treatment from onset of CPP (p = 0.0245)
were found to be significantly positively and negatively
associated, respectively (Table 3). Finally, for height gain
after treatment, significant negative associations were
found for BA at baseline (p < 0.0001) and duration of
treatment (p = 0.0002, Table 4).
Male Patients
While auxological outcome analyses are not presented
herein, the descriptive data on growth during treatment,
post-treatment growth, and bone age and predicted
height are presented below. A total of 6 males were
enrolled in the treatment period, and 5 males partici-
pated in the long-term follow-up period. At baseline,
the mean age of the 6 males was 7.5 years and on aver-
age, BA was advanced over CA by 3.2 years. Treatment
with leuprolide acetate 1-month depot rapidly controlled
the advancement in BA, with mean ΔBA/ΔCA of 1.2
after the first year of treatment. Mean growth rate dur-
ing treatment was reduced from 9.6 cm/year at baseline
to 4.5-9 cm/year during the first 72 weeks and 4.5-6
cm/year from week 72 through week 192, respectively.
The mean incremental growth rate was 2.0 cm/year at
the end of treatment; however, following withdrawal of
study drug, the rate increased to 4.5 cm/year at the 24-
week follow-up visit. The mean final adult height (n =
3) during follow-up was 4.7 cm less than the PAH at
baseline. None of the male patients had final adult
heights recorded at adulthood (after age 18).
Discussion
The results of this prospective, longitudinal study show
that leuprolide acetate 1-month depot effectively sup-
pressed the advanced growth rate and rate of bone
maturation in females with CPP who were naïve to
treatment with GnRHa, similar to the effects observed
in previous studies [20-24]. After discontinuation of
study drug, a small increase in growth rate was observed
during the first year post-treatment, suggesting the
occurrence of a limited pubertal growth spurt. Further-
more, on average, patients in this study population
Table 1 Pretreatment subject demographics and baseline
characteristics
Female Patients
Characteristic N = 49
Race, n (%)
Caucasian 30 (61.2)
African American 11 (22.4)
Asian 0
Hispanic 8 (16.3)
Age, years
Mean (SD) 7.3 (1.9)
Range 1.2-9.4
Weight, kg
Mean (SD) 33.6 (9.72)
Range 13.0-52.2
Height, cm
Mean (SD) 131.6 (14.97)
Range 84.6-154.7
Height Standardized Score
Mean (SD) 1.5 (1.29)
Range -1.4-3.4
Tanner Stage, n (%)
Breast/Genitalia I 1 (2.0)
a
II 9 (18.4)
III 25 (51.0)
IV 13 (26.5)
V 1 (2.0)
Growth Velocity, cm/yr
Mean (SD) 10.7 (3.40)
Range 5.5-21.2
BA, years
Mean (SD) 10.2 (2.13)
Range 2.5-12.1
BA - CA, years
Mean (SD) 3.0 (0.80)
Range 1.3-4.5
History of Menstrual Bleeding, n (%)
No 36 (75)
Yes 12 (25)
aA one year old patient was enrolled in the trial with breast Tanner stage I
based on qualifying peak stimulated LH (84.7 IU/L) and E2 (90 pg/mL).
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Page 4 of 9Figure 2 Mean ± SE growth rates for females.I n c r e m e n t a lg r o w t hr a t e sw e r ec a l c u l a t e de v e r y6m o n t h s .T h eb a s e l i n eg r o w t hr a t ew a s
defined as the growth rate for 1 year prior to the start of study drug. Numbers reflect available results.
Figure 3 Change in bone age to change in chronological age during each year of treatment for females. The ratio of the change in BA
from the previous visit to the change in CA from the previous visit was calculated at approximately one year intervals. Numbers reflect available
results
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Page 5 of 9Figure 4 Height outcomes for females during the study. Adult height includes data from patients whose height was collected at adulthood
after age 18. For patients who were missing adulthood height data, adult height was established when their growth velocity was <1 cm/year or
bone age was ≥14 years during the follow-up period.
Figure 5 Height standardized scores for females during the study. The pretreatment baseline is the mean standardized height score of
patients before initiation of leuprolide acetate therapy. The height at the end of treatment refers to the mean standardized height score for
patients at the end of the treatment period. Adult height includes standardized scores for those patients whose height was collected at
adulthood after age 18. For those without adult height available, adult height was established when their growth velocity was <1 cm/year or
bone age was ≥14 years during the follow-up period.
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after treatment with leuprolide acetate 1-month depot.
Using the Bayley-Pinneau method at baseline to pre-
dict the adult height of our study population, adult
heights were on average 4.0 cm greater than PAH at
onset of treatment with leuprolide acetate among female
patients. This is consistent with previous studies using
depot GnRHa for CPP, which have demonstrated that
females between the ages of 6-8 years have a moderate
height increase that ranges from 4.5 cm to 7.2 cm
[6,25]. While studies have failed to show benefit if treat-
ment is begun after age 8 years [26], this does not take
into account subsequent diminution of growth potential
without treatment. Some studies suggest that the Bay-
ley-Pinneau method may over-predict adult height
among those with advanced skeletal age by several cen-
timeters at baseline [2,7,27]. The 30 patients who had
adult heights in this study had a mean HtSDS of -0.1,
which indicates that their mean height was within the
range of target heights equivalent to that of the normal
population. Twenty-four of the 29 patients with target
heights reached their target height range.
Similar to previous studies (11, 15, 19, 21, 22, 26-28),
we used multiple linear regression to identify factors
that may affect height gain from baseline and from the
end of treatment and final adult height in females with
CPP. Factors having significant correlation by multiple
linear regression analyses (Tables 2, 3, and 4) are dis-
cussed below.
Factors Influencing Adult Height
The two factors that explained 82% of the variability in
adult height were HtSDS score at baseline and average
growth rate during treatment. Both were positively cor-
related and similarly identified as positive factors in a
previous study in determining patients who may benefit
the most with regard to height gain from leuprolide
acetate 1-month depot therapy [20]. The positive corre-
lation between growth rate during treatment and adult
height highlights the importance of monitoring the level
of growth rate suppression during treatment Adequate
Table 2 Analysis of factors significantly associated with
adult height in females
Adult Height
a
Univariate Analysis Correlation Coefficient P-value
At the start of therapy
CA (yr) -0.37 0.0348
BA (yr) -0.38 0.0306
Peak FSH 0.35 0.0466
Growth rate 0.39 0.0336
Height SDS 0.82 <.0001
Target height 0.53 0.0019
During therapy
Averaged growth rate 0.62 0.0001
At the end of therapy
Height SDS 0.82 <.0001
Multiple Linear Regression Beta
Coefficient
P-value R
2
Average growth rate during
treatment
3.05 0.0002
Height SDS at baseline 5.11 <0.0001 0.82
aAdult height was established when the height was associated with a growth
velocity of <1 cm/year or a bone age ≥14 years in females
Table 3 Analysis of factors significantly associated with
gain over predicted adult height
Gain Over Baseline Predicted Adult Height
a
Univariate Analysis Correlation Coefficient P-value
At the start of therapy
CA (yr) -0.43 0.0221
BA minus CA 0.53 0.004
Time to treatment from onset
of CPP (yr)
-0.39 0.0395
During therapy
Duration of the treatment 0.52 0.0048
At the end of therapy
CA 0.40 0.0369
Multiple Linear Regression Beta
Coefficient
P-value R
2
BA-CA at baseline 3.37 0.0028
Time to Treatment from onset
of CPP (yr)
-3.84 0.0245 0.41
aAdult height minus predicted mature height at baseline
Table 4 Analysis of factors significantly associated with
height gain after treatment
Height Gain After Treatment
b
Univariate Analysis Correlation Coefficient P-value
At the start of therapy
CA (yr) -0.58 0.0005
BA (yr) -0.73 <.0001
BA minus CA -0.62 0.0001
Peak FSH 0.38 0.0344
Growth rate 0.44 0.0151
During therapy
Duration of the treatment 0.39 0.0292
Averaged growth rate 0.58 0.0006
ΔBA/ΔCA 0.54 0.0015
Basal FSH -0.36 0.0447
At the end of therapy
BA -0.63 0.0001
Multiple Linear Regression Beta Coefficient P-value R
2
BA at baseline -3.08 <0.0001
Duration of treatment -1.87 0.0002 0.72
aFinal adult height minus height at the end of treatment
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positive final growth outcomes in our study population.
The growth rates observed in this study (5-6 cm/year
during the first 72 weeks of therapy and 4-4.5 cm/year
from week 72 to week 192) were similar to growth rates
observed in normal prepubertal children of these ages.
Unlike prior reports and common expectations, CA at
onset of therapy did not predict height outcome. This is
likely related to the diversity of age at onset of puberty.
Factors Influencing Height Gain Over PAH at Baseline
In the multiple linear regression for height gain over
PAH at baseline, the advancement of BA over CA at
baseline was a strong positive predictor, and time to
treatment from onset of CPP was a strong negative
predictor. This indicates that the greater the advance-
ment of BA over CA at basel i n ea n dt h es h o r t e rt h e
interval between onset of CPP and the initiation of
treatment, the greater the height gain (defined as adult
height minus predicted mature height at baseline).
This observation is similar to results reported by Mul
et al. [12]. Overall, the advancement of BA over CA at
baseline and the time to treatment from onset of CPP
accounted for 41% of the variability in height gain.
The finding that advancement in BA at the onset of
therapy is a positive predictor of height gain over PAH
may seem inconsistent with the previously described
inverse relationship of BA at onset of therapy and
adult height [20]. Because subjects with a more
advanced BA have a lower PAH at the onset of ther-
apy, halting advancement of BA during GnRHa therapy
appears to result in a greater gain in height than the
initial predicted height. This would explain the positive
predictor of height gain, but not actual adult height.
Hence, there appears to be a greater “gain back”
growth potential among those in this study having
more advanced BAs at onset of therapy.
Factors Influencing Height Gain After Stopping Therapy
The duration of therapy had a negative association with
the height gain after stopping therapy. Previous studies
have shown no association between duration of therapy
and height gain after therapy [20,25]. The negative cor-
relation between BA at baseline and height gain after
stopping therapy is expected, and was observed by Brito
et al [20]. The two factors of treatment duration and BA
at baseline explain 72% of the variance in height gain
after treatment. The univariate analysis showing a corre-
lation between ΔBA/ΔCA and growth after therapy does
not persist with the multiple linear regression analyses;
hence, this is not a major factor. The difference in the
results between the univariate and multiple linear
regression analyses might be explained by the consider-
able variation in BAs. At the onset of therapy, BA would
be expected to continue to advance until typical puber-
tal BA is reached. The ratio, therefore, may reflect con-
siderable variation.
In summary, treatment with leuprolide acetate 1-
month depot increased adult height over the PAH. In
addition, the HtSDS was equivalent to that of the nor-
mal population, indicating that these patients had on
average nearly achieved the height of their peers without
CPP. Overall, treatment with leuprolide acetate 1-month
depot preserved adult height potential and resulted in
clinically meaningful height gains over PAH. The results
of this study confirm that in females, early initiation of
treatment from the onset of CPP results in the greatest
increase in height. In addition, female patients with the
greatest advance in BA experience the most height gain
over PAH with GnRHa treatment, and maintaining
growth rates within that of normal prepubertal children
during GnRHa treatment may result in the highest adult
height outcome.
Acknowledgements
Financial support for this study was provided by Abbott Laboratories,
formerly TAP Pharmaceutical Products Inc. Medical writing support was
provided by Amanda J. Fein, PhD and Theresa J. Peterson, PhD on behalf of
Abbott. The authors would like to thank the following authors for their
participation in the study: Barry B. Bercu, MD; Clifford Bloch, MD; Stuart A
Chalew, MD; Robert Clemons, MD; Felix A. Conte, MD; Raymond Hintz, MD;
Michael S. Kappy, MD; Georgeanna J. Klingensmith, MD; and Edward O.
Reiter, MD.
Author details
1The Milton S. Hershey Medical Center, College of Medicine, Pennsylvania
State University, Hershey, PA 17033, USA.
2Section of Pediatric Endocrinology
and Diabetology, James Whitcomb Riley Hospital for Children, School of
Medicine, Indiana University, Indianapolis, IN 46202, USA.
3Division of
Pediatric Endocrinology and Diabetes, Room G313, Stanford University
Medical Center, Stanford, CA 94305, USA.
4Abbott Laboratories, 200 Abbott
Park Road, Abbott Park, IL 60064, USA.
Authors’ contributions
PL was involved in the original protocol, the laboratory assessments, the
planning and execution of the phase 4 (follow-up) study as well as the
preparation of the manuscript. EKN and JF participated in data collection
and interpretation and manuscript preparation. LL and DY performed the
statistical analysis and participated in drafting the manuscript. CMG and KC
participated in interpreting the data and manuscript preparation. All authors
read and approved the final manuscript.
Competing interests
PAL has been a consultant for Abbott and Novo Nordisk with grants from
Abbott, Eli Lilly, Novo Nordisk, Pfizer, and Ipsen. EKN has received grant/
research support from and has been a consultant and scientific advisory
board member for Abbott. JF has been a scientific advisory board member
for Abbott. DY, LL, CMG, and KC are all employees of Abbott and LL, CMG,
and KC all own Abbott stock.
Received: 16 June 2011 Accepted: 12 July 2011 Published: 12 July 2011
References
1. Brauner R: Central precocious puberty in girls: prediction of the
aetiology. J Pediatr Endocrinol Metab 2005, 18(9):845-7.
2. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, Antoniazzi F, et al:
Consensus statement on the use of gonadotropin-releasing hormone
analogs in children. Pediatrics 2009, 123(4):e752-62.
Lee et al. International Journal of Pediatric Endocrinology 2011, 2011:7
http://www.ijpeonline.com/content/2011/1/7
Page 8 of 93. Parker KL, Lee PA: Depot leuprolide acetate for treatment of precocious
puberty. The Journal of clinical endocrinology and metabolism 1989,
69(3):689-91.
4. Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Antoniazzi F,
et al: Analysis of the factors affecting auxological response to GnRH
agonist treatment and final height outcome in girls with idiopathic
central precocious puberty. European journal of endocrinology/European
Federation of Endocrine Societies 1999, 141(2):140-4.
5. Brauner R, Adan L, Malandry F, Zantleifer D: Adult height in girls with
idiopathic true precocious puberty. The Journal of clinical endocrinology
and metabolism 1994, 79(2):415-20.
6. Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, et al: Final
height after long-term treatment with triptorelin slow release for central
precocious puberty: importance of statural growth after interruption of
treatment. French study group of Decapeptyl in Precocious Puberty. The
Journal of clinical endocrinology and metabolism 1999, 84(6):1973-8.
7. Kauli R, Galatzer A, Kornreich L, Lazar L, Pertzelan A, Laron Z: Final height
of girls with central precocious puberty, untreated versus treated with
cyproterone acetate or GnRH analogue. A comparative study with re-
evaluation of predictions by the Bayley-Pinneau method. Hormone
research 1997, 47(2):54-61.
8. Kaye D, Frankl W, Arditi LI: Probable postcardiotomy syndrome following
implantation of a transvenous pacemaker: report of the first case.
American heart journal 1975, 90(5):627-30.
9. Kreiter M, Burstein S, Rosenfield RL, Moll GW Jr, Cara JF, Yousefzadeh DK,
et al: Preserving adult height potential in girls with idiopathic true
precocious puberty. The Journal of pediatrics 1990, 117(3):364-70.
10. Lanes R, Soros A, Jakubowicz S: Accelerated versus slowly progressive
forms of puberty in girls with precocious and early puberty.
Gonadotropin suppressive effect and final height obtained with two
different analogs. J Pediatr Endocrinol Metab 2004, 17(5):759-66.
11. Leger J, Reynaud R, Czernichow P: Do all girls with apparent idiopathic
precocious puberty require gonadotropin-releasing hormone agonist
treatment? The Journal of pediatrics 2000, 137(6):819-25.
12. Mul D, Oostdijk W, Otten BJ, Rouwe C, Jansen M, Delemarre-van de
Waal HA, et al: Final height after gonadotrophin releasing hormone
agonist treatment for central precocious puberty: the Dutch experience.
J Pediatr Endocrinol Metab 2000, 13(Suppl 1):765-72.
13. Pasquino AM, Pucarelli I, Segni M, Matrunola M, Cerroni F: Adult height in
girls with central precocious puberty treated with gonadotropin-
releasing hormone analogues and growth hormone. The Journal of
clinical endocrinology and metabolism 1999, 84(2):449-52.
14. Clemons RD, Kappy MS, Stuart TE, Perelman AH, Hoekstra FT: Long-term
effectiveness of depot gonadotropin-releasing hormone analogue in the
treatment of children with central precocious puberty. American journal
of diseases of children (1960) 1993, 147(6):653-7.
15. Neely EK, Hintz RL, Parker B, Bachrach LK, Cohen P, Olney R, et al: Two-year
results of treatment with depot leuprolide acetate for central precocious
puberty. The Journal of pediatrics 1992, 121(4):634-40.
16. Tanaka T, Niimi H, Matsuo N, Fujieda K, Tachibana K, Ohyama K, et al:
Results of long-term follow-up after treatment of central precocious
puberty with leuprorelin acetate: evaluation of effectiveness of
treatment and recovery of gonadal function. The TAP-144-SR Japanese
Study Group on Central Precocious Puberty. The Journal of clinical
endocrinology and metabolism 2005, 90(3):1371-6.
17. Neely EK, Lee PA, Bloch CA, Larsen L, Yang D, Mattia-Goldberg C, et al:
Leuprolide acetate 1-month depot for central precocious puberty:
hormonal suppression and recovery. Int J Pediatr Endocrinol 2010,
2010:398639.
18. Roche AF, Chumlea WC, Thissen D: Assessing the skeletal maturity of the
hand wrist: FELS method. Springfield, IL: Charles C. Thomas; 1988.
19. Bayley N, Pinneau SR: Tables for predicting adult height from skeletal
age: revised for use with the Greulich-Pyle hand standards. The Journal
of pediatrics 1952, 40(4):423-41.
20. Brito VN, Latronico AC, Cukier P, Teles MG, Silveira LF, Arnhold IJ, et al:
Factors determining normal adult height in girls with gonadotropin-
dependent precocious puberty treated with depot gonadotropin-
releasing hormone analogs. The Journal of clinical endocrinology and
metabolism 2008, 93(7):2662-9.
21. Badaru A, Wilson DM, Bachrach LK, Fechner P, Gandrud LM, Durham E,
et al: Sequential comparisons of one-month and three-month depot
leuprolide regimens in central precocious puberty. The Journal of clinical
endocrinology and metabolism 2006, 91(5):1862-7.
22. Carel JC, Lahlou N, Jaramillo O, Montauban V, Teinturier C, Colle M, et al:
Treatment of central precocious puberty by subcutaneous injections of
leuprorelin 3-month depot (11.25 mg). The Journal of clinical
endocrinology and metabolism 2002, 87(9):4111-6.
23. Eugster EA, Clarke W, Kletter GB, Lee PA, Neely EK, Reiter EO, et al: Efficacy
and safety of histrelin subdermal implant in children with central
precocious puberty: a multicenter trial. The Journal of clinical
endocrinology and metabolism 2007, 92(5):1697-704.
24. Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R: Long-
term observation of 87 girls with idiopathic central precocious puberty
treated with gonadotropin-releasing hormone analogs: impact on adult
height, body mass index, bone mineral content, and reproductive
function. The Journal of clinical endocrinology and metabolism 2008,
93(1):190-5.
25. Lazar L, Padoa A, Phillip M: Growth pattern and final height after
cessation of gonadotropin-suppressive therapy in girls with central
sexual precocity. The Journal of clinical endocrinology and metabolism 2007,
92(9):3483-9.
26. Magiakou MA, Manousaki D, Papadaki M, Hadjidakis D, Levidou G, Vakaki M,
et al: The efficacy and safety of gonadotropin-releasing hormone analog
treatment in childhood and adolescence: a single center, long-term
follow-up study. The Journal of clinical endocrinology and metabolism 2010,
95(1):109-17.
27. Bar A, Linder B, Sobel EH, Saenger P, DiMartino-Nardi J: Bayley-Pinneau
method of height prediction in girls with central precocious puberty:
correlation with adult height. The Journal of pediatrics 1995, 126(6):955-8.
doi:10.1186/1687-9856-2011-7
Cite this article as: Lee et al.: Efficacy of Leuprolide Acetate 1-Month
Depot for Central Precocious Puberty (CPP): Growth Outcomes During a
Prospective, Longitudinal Study. International Journal of Pediatric
Endocrinology 2011 2011:7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lee et al. International Journal of Pediatric Endocrinology 2011, 2011:7
http://www.ijpeonline.com/content/2011/1/7
Page 9 of 9